Multi-micronutrient Supplementation During Peri-conception and Congenital Heart Disease
Primary Purpose
Congenital Heart Disease
Status
Completed
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Vitamin B Complex and Folic Acid
Iron and Folic Acid
Folic Acid
Sponsored by
About this trial
This is an interventional prevention trial for Congenital Heart Disease
Eligibility Criteria
Inclusion Criteria:
- Women of reproductive age (15-49 years) who reside in the study areas;
- Women who are prepared for pregnancy in 1-3 months or have already been pregnant for less than 20 months;
- Women who have provided written informed consent.
Exclusion Criteria:
- Women who have already taken supplements containing vitamin B complex, iron, or folic acid for more than two weeks at enrollment;
- Women who have given birth to children with congenital heart disease or other birth defects before;
- Women with diabetes;
- women with severe heart, liver or kidney disease.
Sites / Locations
- Xi'an Jiaotong University College of Medicine
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Active Comparator
Arm Label
Vitamin B Complex and Folic Acid
Iron and Folic Acid
Folic Acid
Arm Description
Daily supplements containing vitamin B1 (2 mg), vitamin B2 (2 mg), vitamin B6 (2 mg), vitamin B12 (2 μg), calcium pantothenate (2 mg), nicotinamide (15 mg) and folic acid (0.4 mg).
Daily supplements of iron (60 mg) and folic acid (0.4 mg).
Daily supplement of 0.4 mg folic acid.
Outcomes
Primary Outcome Measures
Neonatal pulse oximetry oxygen saturation measured by pulse oximetry
Neonatal pulse oximetry oxygen saturation (SpO2) is tested by pulse oximetry in babies aged between 6 h and 72 h after birth. Pulse oximetry testing is repeated 4 h later if the first measurement is between 90% and 95%. The result of SpO2 will be reported as a dichotomous variable, in which the result is deemed positive if an SpO2 less than 95% is obtained both on the right hand and on either foot on two measures, separated by 4 h; a difference between the two extremities was more than 3% on two measures, separated by 4 h; or any measure is less than 90%. The result of SpO2 will also be reported as a continuous variable.
Secondary Outcome Measures
Incidence of congenital heart disease and the subtypes
Congenital heart disease will be diagnosed by trained clinicians with the help of echocardiography, pulse oximetry, clinical examination, cardiac surgery, or autopsy. The incidence of congenital heart disease and the subtypes will be reported in each group.
Incidence of birth defects and the subtypes
Birth defects will be diagnosed by trained clinicians. The incidence of birth defects and the subtypes will be reported in each group.
Birth weight measured by baby scale
Birth weight will be measured within 1 hour of delivery using a baby scale with the precision to the nearest 50 gram.
Incidence of low birth weight
Birth weight will be measured within 1 hour of delivery using a baby scale. The incidence of low birth weight will be reported in each group based on the criteria of birth weight less than 2500 gram.
Gestational age at birth
Gestational age at birth will be measured as completed days based on the last menstrual period.
Incidence of preterm birth
Gestational age at birth will be measured as completed days based on the last menstrual period. The incidence of preterm birth (infant born less than 37 weeks gestational age) will be reported in each group.
Incidence of perinatal mortality
The incidence of perinatal mortality (Infants death between 28 weeks of gestational duration and 7 days after delivery) will be reported in each group.
Incidence of stillbirth
The incidence of stillbirth (infants death at delivery) will be reported in each group.
Incidence of neonatal mortality
The incidence of neonatal mortality (infants death during the first 28 days after birth) will be reported in each group.
Incidence of early neonatal mortality
The incidence of early neonatal mortality (infants death during the first 7 days after birth) will be reported in each group.
Incidence of pregnancy complications: hypertension, preeclampsia, antepartum haemorrhage, and infections
Pregnancy complications (hypertension, preeclampsia, antepartum haemorrhage, and infections) will be diagnosed by trained clinicians during antenatal care checks. All information will be recorded in the pregnant women's medical records of antenatal care checks and delivery. The incidence of hypertension, preeclampsia, antepartum haemorrhage, and infections among participants will be reported in each group.
Full Information
NCT ID
NCT02537392
First Posted
August 27, 2015
Last Updated
July 6, 2020
Sponsor
Health Science Center of Xi'an Jiaotong University
1. Study Identification
Unique Protocol Identification Number
NCT02537392
Brief Title
Multi-micronutrient Supplementation During Peri-conception and Congenital Heart Disease
Official Title
Primary Prevention of Multi-micronutrient Supplementation During Peri-conception Against Congenital Heart Disease: A Community-based Randomised Controlled Trial in China
Study Type
Interventional
2. Study Status
Record Verification Date
July 2020
Overall Recruitment Status
Completed
Study Start Date
September 2015 (Actual)
Primary Completion Date
December 2019 (Actual)
Study Completion Date
December 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Health Science Center of Xi'an Jiaotong University
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to determine whether daily oral supplements of vitamin B complex along with folic acid or supplements of iron plus folic acid given to women during peri-conception can reduce the risk of congenital heart disease when compared with folic acid alone.
Detailed Description
Congenital heart disease (CHD) is among the most prevalent congenital abnormalities with an incidence of about 8-12/1,000 live births, and is also the leading cause of infant morbidity and death from birth defects. A series of studies pointed out that the poor nutritional status of the mother during peri-conception might be the important cause of CHD. In maternal folic acid/ vitamin B deficiency homocysteine accumulates in the serum, and elevated circulating homocysteine concentrations have been associated with the risk of CHD. However, it is still questionable whether multiple vitamin B supplements during peri-conception can reduce CHD risk more effectively compared with the supplement of folic acid alone. Moreover, one randomized controlled trial performed in Shaanxi China confirmed that the supplement of iron and folic acid during pregnancy can significantly reduce early neonatal deaths. It is noteworthy that one-fourth of newborn deaths are attributable to birth defects. Thus, it is worthwhile to investigate whether iron supplement can reduce the risk of CHD.
This community-based randomized controlled trial will assess and compare the impact of daily oral supplements of vitamin B complex along with folic acid or supplements of iron plus folic acid vs. folic acid alone given to women during peri-conception on CHD. It will also assess the effects of the three different supplementations on other pregnancy outcomes and maternal health. The study will be conducted in three rural poor counties including Xunyi, Changwu, and Bin, which are located in Shaanxi Province of Northwest China. All participants will sign informed consent before the study. The investigators hypothesize that the newborn infants of women receiving supplements of vitamin B complex along with folic acid or supplements of iron plus folic acid will experience a reduction in the prevalence of infants with the pulse oxygen saturation less than 95% and other adverse pregnancy outcomes compared with those receiving folic acid alone. The results of this trial will provide evidence needed to formulate policy on maternal micronutrient supplementation during peri-conception and the rationale for the necessary investment of public funds to implement appropriate programs against birth defects.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Congenital Heart Disease
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
7315 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Vitamin B Complex and Folic Acid
Arm Type
Experimental
Arm Description
Daily supplements containing vitamin B1 (2 mg), vitamin B2 (2 mg), vitamin B6 (2 mg), vitamin B12 (2 μg), calcium pantothenate (2 mg), nicotinamide (15 mg) and folic acid (0.4 mg).
Arm Title
Iron and Folic Acid
Arm Type
Experimental
Arm Description
Daily supplements of iron (60 mg) and folic acid (0.4 mg).
Arm Title
Folic Acid
Arm Type
Active Comparator
Arm Description
Daily supplement of 0.4 mg folic acid.
Intervention Type
Dietary Supplement
Intervention Name(s)
Vitamin B Complex and Folic Acid
Intervention Description
Daily oral dose containing 2 mg vitamin B1, 2 mg vitamin B2, 2 mg vitamin B6, 2 μg vitamin B12, 2 mg calcium pantothenate, 15 mg nicotinamide and 0.4 mg folic acid.
Intervention Type
Dietary Supplement
Intervention Name(s)
Iron and Folic Acid
Intervention Description
Daily oral dose of 60 mg iron and 0.4 mg folic acid.
Intervention Type
Dietary Supplement
Intervention Name(s)
Folic Acid
Intervention Description
Daily oral dose of 0.4 mg folic acid.
Primary Outcome Measure Information:
Title
Neonatal pulse oximetry oxygen saturation measured by pulse oximetry
Description
Neonatal pulse oximetry oxygen saturation (SpO2) is tested by pulse oximetry in babies aged between 6 h and 72 h after birth. Pulse oximetry testing is repeated 4 h later if the first measurement is between 90% and 95%. The result of SpO2 will be reported as a dichotomous variable, in which the result is deemed positive if an SpO2 less than 95% is obtained both on the right hand and on either foot on two measures, separated by 4 h; a difference between the two extremities was more than 3% on two measures, separated by 4 h; or any measure is less than 90%. The result of SpO2 will also be reported as a continuous variable.
Time Frame
6-72 hours after delivery
Secondary Outcome Measure Information:
Title
Incidence of congenital heart disease and the subtypes
Description
Congenital heart disease will be diagnosed by trained clinicians with the help of echocardiography, pulse oximetry, clinical examination, cardiac surgery, or autopsy. The incidence of congenital heart disease and the subtypes will be reported in each group.
Time Frame
Half a year after delivery
Title
Incidence of birth defects and the subtypes
Description
Birth defects will be diagnosed by trained clinicians. The incidence of birth defects and the subtypes will be reported in each group.
Time Frame
Half a year after delivery
Title
Birth weight measured by baby scale
Description
Birth weight will be measured within 1 hour of delivery using a baby scale with the precision to the nearest 50 gram.
Time Frame
Within 1 hours of delivery
Title
Incidence of low birth weight
Description
Birth weight will be measured within 1 hour of delivery using a baby scale. The incidence of low birth weight will be reported in each group based on the criteria of birth weight less than 2500 gram.
Time Frame
Within 1 hour of delivery
Title
Gestational age at birth
Description
Gestational age at birth will be measured as completed days based on the last menstrual period.
Time Frame
At delivery
Title
Incidence of preterm birth
Description
Gestational age at birth will be measured as completed days based on the last menstrual period. The incidence of preterm birth (infant born less than 37 weeks gestational age) will be reported in each group.
Time Frame
At delivery
Title
Incidence of perinatal mortality
Description
The incidence of perinatal mortality (Infants death between 28 weeks of gestational duration and 7 days after delivery) will be reported in each group.
Time Frame
Between 28 weeks of gestational duration and 7 days after delivery
Title
Incidence of stillbirth
Description
The incidence of stillbirth (infants death at delivery) will be reported in each group.
Time Frame
At delivery
Title
Incidence of neonatal mortality
Description
The incidence of neonatal mortality (infants death during the first 28 days after birth) will be reported in each group.
Time Frame
First 28 days after birth
Title
Incidence of early neonatal mortality
Description
The incidence of early neonatal mortality (infants death during the first 7 days after birth) will be reported in each group.
Time Frame
First 7 days after birth
Title
Incidence of pregnancy complications: hypertension, preeclampsia, antepartum haemorrhage, and infections
Description
Pregnancy complications (hypertension, preeclampsia, antepartum haemorrhage, and infections) will be diagnosed by trained clinicians during antenatal care checks. All information will be recorded in the pregnant women's medical records of antenatal care checks and delivery. The incidence of hypertension, preeclampsia, antepartum haemorrhage, and infections among participants will be reported in each group.
Time Frame
After enrollment until at delivery
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
15 Years
Maximum Age & Unit of Time
49 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Women of reproductive age (15-49 years) who reside in the study areas;
Women who are prepared for pregnancy in 1-3 months or have already been pregnant for less than 20 months;
Women who have provided written informed consent.
Exclusion Criteria:
Women who have already taken supplements containing vitamin B complex, iron, or folic acid for more than two weeks at enrollment;
Women who have given birth to children with congenital heart disease or other birth defects before;
Women with diabetes;
women with severe heart, liver or kidney disease.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hong Yan, Professor
Organizational Affiliation
Health Science Center of Xi'an Jiaotong University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Xi'an Jiaotong University College of Medicine
City
Xi'an
State/Province
Shaanxi
ZIP/Postal Code
710061
Country
China
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
31056148
Citation
Mi B, Wen X, Li S, Liu D, Lei F, Liu R, Shen Y, Chen Y, Zeng L, Liu X, Dang S, Yan H. Vegetable dietary pattern associated with low risk of preeclampsia possibly through reducing proteinuria. Pregnancy Hypertens. 2019 Apr;16:131-138. doi: 10.1016/j.preghy.2019.04.001. Epub 2019 Apr 8.
Results Reference
derived
Learn more about this trial
Multi-micronutrient Supplementation During Peri-conception and Congenital Heart Disease
We'll reach out to this number within 24 hrs